Empaveli

Pharma

Biogen lays out $5.6B to acquire Apellis

Biogen is bulking up in immunology—and paving the way for its nephrology future—with an M&A play that adds two ongoing launches to its marketed lineup.

Fraiser Kansteiner Mar 31, 2026 10:32am

Apellis reports 4% sales drop for eye disease med Syfovre

Jan 12, 2026 1:06pm

Apellis snatches broad kidney disease expansion for Empaveli

Jul 28, 2025 8:00pm

Sobi places $300M bet on Empaveli in partnership with Apellis

Jul 1, 2025 11:28am

Apellis' Syfovre faces tough road ahead in GA market: analyst

May 14, 2025 11:10am

Novartis' Fabhalta nod in C3G leaves room for rival Apellis

Mar 21, 2025 10:37am